HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tsutomu Hirano Selected Research

Cholesterol Esters (Cholesteryl Esters)

4/2014A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
9/2010Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tsutomu Hirano Research Topics

Disease

40Type 2 Diabetes Mellitus (MODY)
01/2024 - 01/2002
36Atherosclerosis
04/2023 - 03/2003
25Insulin Resistance
07/2023 - 01/2002
20Coronary Artery Disease (Coronary Atherosclerosis)
05/2024 - 01/2002
17Hypertriglyceridemia
04/2024 - 01/2002
17Coronary Disease (Coronary Heart Disease)
01/2012 - 01/2002
13Inflammation (Inflammations)
05/2022 - 06/2002
13Hyperlipidemias (Hyperlipidemia)
06/2015 - 01/2002
12Cardiovascular Diseases (Cardiovascular Disease)
07/2023 - 11/2008
12Dyslipidemias (Dyslipidemia)
07/2023 - 01/2002
10Hypertension (High Blood Pressure)
07/2020 - 06/2002
10Atherosclerotic Plaque (Atheroma)
05/2020 - 06/2006
10Body Weight (Weight, Body)
02/2020 - 07/2012
7Obesity
07/2023 - 06/2002
7Hyperglycemia
07/2020 - 04/2014
7Hypercholesterolemia
06/2017 - 01/2003
5Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2022 - 12/2006
5Proteinuria
04/2022 - 06/2003
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
07/2020 - 08/2010
5Carotid Artery Diseases
05/2019 - 02/2007
5Diabetic Nephropathies (Diabetic Nephropathy)
09/2018 - 06/2003
4Chronic Kidney Failure (Chronic Renal Failure)
02/2022 - 04/2007
4Glucose Intolerance
01/2017 - 06/2002
4Diabetes Mellitus
01/2014 - 01/2002
3Nephrotic Syndrome (Syndrome, Nephrotic)
02/2022 - 05/2015
3Diabetic Retinopathy (Retinopathy, Diabetic)
01/2022 - 12/2008
3Hyperplasia
01/2018 - 10/2017
3Fibrosis (Cirrhosis)
08/2016 - 03/2012
3Acute Coronary Syndrome
01/2014 - 11/2006
3Myocardial Infarction
10/2008 - 09/2003
2Autoimmune Diseases (Autoimmune Disease)
08/2023 - 08/2010
2Stroke (Strokes)
04/2023 - 01/2014
2Hypoglycemia (Reactive Hypoglycemia)
02/2020 - 01/2019
2Heart Failure
01/2020 - 01/2014
2Chronic Renal Insufficiency
01/2016 - 04/2014
2Hypoproteinemia
06/2015 - 04/2014

Drug/Important Bio-Agent (IBA)

51oxidized low density lipoproteinIBA
05/2024 - 01/2002
28Glucose (Dextrose)FDA LinkGeneric
09/2021 - 01/2002
24Triglycerides (Triacylglycerol)IBA
04/2024 - 01/2002
21ApolipoproteinsIBA
05/2024 - 08/2002
21LDL CholesterolIBA
05/2024 - 08/2002
18LipidsIBA
07/2023 - 07/2003
16Apolipoproteins E (ApoE)IBA
01/2023 - 09/2010
15LDL Lipoproteins (beta Lipoproteins)IBA
07/2023 - 01/2002
14Insulin (Novolin)FDA Link
06/2018 - 01/2002
13HDL CholesterolIBA
05/2024 - 07/2003
12Lipoproteins (Lipoprotein)IBA
05/2022 - 01/2002
12Peptides (Polypeptides)IBA
08/2016 - 10/2005
11CholesterolIBA
01/2023 - 12/2002
10Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2023 - 01/2002
9Biomarkers (Surrogate Marker)IBA
07/2023 - 10/2008
8HDL LipoproteinsIBA
01/2023 - 05/2004
7AdiponectinIBA
01/2018 - 06/2002
6Dipeptidyl-Peptidase IV InhibitorsIBA
09/2021 - 01/2016
6IncretinsIBA
02/2020 - 01/2010
6LiraglutideFDA Link
02/2019 - 04/2014
6Vasoconstrictor AgentsIBA
04/2017 - 10/2005
6urotensin IIIBA
06/2009 - 10/2005
6FructoseIBA
01/2008 - 06/2002
5Apolipoproteins B (ApoB)IBA
05/2024 - 08/2002
5Glucagon (Glukagon)FDA Link
05/2020 - 01/2013
5Glucagon-Like Peptide 1 (GLP 1)IBA
04/2015 - 01/2010
4Fibric Acids (Fibrates)IBA
05/2022 - 01/2002
43- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA
07/2020 - 09/2015
4dapagliflozinIBA
01/2020 - 01/2015
4Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2019 - 01/2014
4Proteins (Proteins, Gene)FDA Link
10/2016 - 06/2002
3(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
04/2024 - 07/2023
3Streptozocin (Streptozotocin)FDA Link
07/2020 - 10/2003
3Hemoglobins (Hemoglobin)IBA
03/2020 - 01/2014
3gastric inhibitory polypeptide receptorIBA
02/2020 - 08/2016
3Hypoglycemic Agents (Hypoglycemics)IBA
02/2020 - 07/2003
3Angiotensin IIIBA
08/2016 - 04/2006
3pitavastatin (itavastatin)FDA Link
03/2016 - 06/2007
3Messenger RNA (mRNA)IBA
03/2012 - 05/2003
3C-Reactive ProteinIBA
01/2012 - 06/2002
3Heparin (Liquaemin)FDA LinkGeneric
08/2007 - 04/2004
3VLDL LipoproteinsIBA
05/2007 - 08/2002
3olmesartanIBA
01/2006 - 04/2004
2AutoantibodiesIBA
08/2023 - 11/2019
2pigment epithelium-derived factorIBA
03/2021 - 03/2015
2AlbuminsIBA
03/2020 - 07/2003
2Glucagon-Like Peptide-1 Receptor AgonistsIBA
02/2020 - 01/2019
2EnzymesIBA
11/2019 - 04/2007
2ImmunosorbentsIBA
11/2019 - 04/2007
2AdipokinesIBA
01/2019 - 05/2016
2LipopolysaccharidesIBA
01/2018 - 01/2018
2Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2018 - 01/2013
2CollagenIBA
01/2018 - 10/2016
2Sitagliptin Phosphate (Januvia)FDA Link
11/2017 - 01/2017
2Ezetimibe (Zetia)FDA Link
06/2017 - 03/2012
2Sodium-Glucose Transport ProteinsIBA
01/2017 - 01/2015
2Proprotein Convertase 9IBA
09/2016 - 05/2013
2ChylomicronsIBA
04/2014 - 09/2003
2Cholesterol Esters (Cholesteryl Esters)IBA
04/2014 - 09/2010

Therapy/Procedure

16Therapeutics
04/2024 - 07/2003
4Renal Dialysis (Hemodialysis)
04/2014 - 06/2003
3Blood Component Removal (Apheresis)
02/2022 - 05/2015
2Aftercare (After-Treatment)
01/2019 - 06/2015
2Percutaneous Coronary Intervention
03/2015 - 08/2007